[A22-128] Pembrolizumab (renal cell carcinoma) – Addendum to Commission A22-71
Last updated 19.01.2023
Project no.:
A22-128
Commission:
Commission awarded on 06.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adjuvant treatment of adult patients with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
After addendum now hint of non-quantifiable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-71 | Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-01-19 A G-BA decision was published.